Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

about

Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

P2860

Q58804575-610E5CFF-9B65-4B23-AD1F-1D9B983E3706

P2860

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Item

http://www.wikidata.org/entity/Q52679023

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@en

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@nl

type

Item

label

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@en

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@nl

prefLabel

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@en

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@nl

P1476

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

@en

P2093

Carlo Gambacorti-Passerini

http://www.w3.org/2001/XMLSchema#string

Enrico Patrucco

http://www.w3.org/2001/XMLSchema#string

Ines Mota

http://www.w3.org/2001/XMLSchema#string

Roberto Chiarle

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase: signalling in development and disease

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Cell signaling by receptor tyrosine kinases

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

P31

scholarly article

P356

10.3390/CANCERS10030062

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luca Mologni

Geeta Geeta Sharma

P577

2018-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29495603

http://www.w3.org/2001/XMLSchema#string

P932

5876637

http://www.w3.org/2001/XMLSchema#string

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

about

P2860

P2860

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932